These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 25400539)

  • 41. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
    Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
    Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative multimodal multiparametric imaging in Alzheimer's disease.
    Zhao Q; Chen X; Zhou Y
    Brain Inform; 2016 Mar; 3(1):29-37. PubMed ID: 27747597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.
    Zimmer ER; Parent MJ; Cuello AC; Gauthier S; Rosa-Neto P
    Trends Neurosci; 2014 Nov; 37(11):629-41. PubMed ID: 25151336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders.
    Raji CA; Torosyan N; Silverman DHS
    J Alzheimers Dis; 2020; 77(3):935-947. PubMed ID: 32804147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Amyloid Positron Emission Tomography in the Therapeutic Strategies for Alzheimer's Disease].
    Ishii K
    Brain Nerve; 2017 Jul; 69(7):809-818. PubMed ID: 28739995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.
    Wang X; Huang W; Su L; Xing Y; Jessen F; Sun Y; Shu N; Han Y
    Mol Neurodegener; 2020 Sep; 15(1):55. PubMed ID: 32962744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.
    Berti V; Polito C; Lombardi G; Ferrari C; Sorbi S; Pupi A
    Neurol Sci; 2016 May; 37(5):663-72. PubMed ID: 26792010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
    Lowe VJ; Lundt ES; Albertson SM; Przybelski SA; Senjem ML; Parisi JE; Kantarci K; Boeve B; Jones DT; Knopman D; Jack CR; Dickson DW; Petersen RC; Murray ME
    Alzheimers Dement; 2019 Jul; 15(7):927-939. PubMed ID: 31175025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI.
    Lowe VJ; Peller PJ; Weigand SD; Montoya Quintero C; Tosakulwong N; Vemuri P; Senjem ML; Jordan L; Jack CR; Knopman D; Petersen RC
    Neurology; 2013 Jun; 80(23):2130-7. PubMed ID: 23645596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research.
    Ford J; Kafetsouli D; Wilson H; Udeh-Momoh C; Politis M; AhmadiAbhari S; Rabiner I; Middleton LT
    J Prev Alzheimers Dis; 2022; 9(1):67-76. PubMed ID: 35098975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
    Pandya S; Kuceyeski A; Raj A;
    J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
    Dickerson BC; Wolk DA;
    Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease.
    Cui J; Zufferey V; Kherif F
    Curr Opin Neurol; 2015 Aug; 28(4):351-7. PubMed ID: 26132531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.